Monoclonal Antibody Therapy in Treating Patients With Recurrent Non-Hodgkin’s Lymphoma

DISEASE CHARACTERISTICS:

Histologically confirmed non-Hodgkin's lymphoma in relapse or refractory to prior treatment
At least 50% of malignant cells on biopsy specimen reactive with the 1D10 antibody OR at least 50% of B cells within tumor reactive with 1D10 if extensive T cell infiltrations present
Measurable or evaluable disease
Circulating tumor cells fewer than 5,000/mm3 (in dose escalation phase only)
Not eligible for curative conventional therapy

PATIENT CHARACTERISTICS:

Age: 18 and over
Performance status: ECOG 0-2
Life expectancy: At least 3 months
Platelet count at least 75,000/mm3
Bilirubin less than 2.5 mg/dL
SGOT less than 3 times upper limit of normal
Creatinine less than 2.0 mg/dL
No New York Heart Association class III or IV heart disease
No clinically significant pulmonary disease
No active serious infection
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception HIV negative

PRIOR CONCURRENT THERAPY:

At least 4 weeks since prior interferon
Concurrent transfusions allowed
At least 4 weeks since prior cytotoxic chemotherapy
No concurrent antineoplastic agents
At least 4 weeks since prior corticosteroids
No concurrent glucocorticoids
At least 4 weeks since prior radiotherapy